- Abiraterone
- Actinium-225
- Active monitoring
- Active surveillance
- Adjuvant therapy
- Advanced prostate cancer
- Aggressive Prostate Cancer
- Androgen Deprivation Therapy (ADT)
- Apalutamide
- ATM
- Benign
- Bicalutamide
- Biopsy
- Bisphosphonates
- Bone Scan
- Brachytherapy
- BRCA (BRCA1, BRCA2)
- Castration-resistant prostate cancer (CRPC)
- CHEK2
- Chemotherapy
- Cryotherapy
- CT Scan
- Darolutamide
- Digital Rectal Palpation
- Disease Progression
- Disease Recurrence
- Docetaxel
- Enzalutamide
- ePRO
- Erectile Dysfunction
- External beam radiotherapy (EBR)
- Faecal Incontinence
- Genetic Factors
- Gleason Score
- GnRH Antagonists
- High intensity interval training (HIIT)
- High-intensity focused ultrasound (HIFU)
- Hormone therapy
- Immunotherapy
- Impotence
- LHRH Agonists
- Localized prostate cancer
- Lutetium-177
- Lymph nodes
- Malignant
- Metastasis
- Metastatic Prostate Cancer
- Molecular tumour board
- MRI Scan
- Multifocal prostate cancer
- Neoadjuvant therapy
- Neoplasm
- Orchiectomy or orchidectomy (Castration)
- Palliative medicine
- PARP-Inhibitor
- Pathologic Examination
- Patient reported outcomes (PRO)
- Placebo
- Prognosis
- Progression
- Prostate
- Prostate Cancer
- Prostate Specific Antigen (PSA)
- Prostate-specific membrane antigen (PSMA)
- Prostatectomy
- PSA test
- Radiation oncologist
- Radiation therapy
- Radioisotope therapy
- Radioligand therapy
- Radiologist
- Radiopharmaceutical therapy
- Radium-223
- Recurrence
- Refractory cancer
- Relapse
- Remission
- Risk Factors
- Scanxiety
- Screening Program
- Secondary cancer
- Standard of care
- Systemic therapy
- Targeted Therapy
- Telehealth
- Telemedicine
- Testosterone
- TNM staging (system)
- Transrectal Ultrasound
- Tumour board
- Urinary Incontinence
- Watchful waiting